ADC Therapeutics Stock Quote ADCT - Stock Price, News, Charts, Message Board, Trades

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Premium

Current Price

3.14

Bid

Ask

Volume

6,944

0.00 Day's Range 0.00

0.9818 52 Week Range 6.04

Market Cap

303.605M

Previous Close

3.21

Open

Last Trade

1139

3.14

(formt)

Last Trade Time

06:25:13

Financial Volume

VWAP

Average Volume (3m)

594,708

Shares Outstanding

96,689,617

Dividend Yield

PE Ratio

-1.32

Earnings Per Share (EPS)

-2.43

Revenue

69.56M

Net Profit

-234.53M

ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's product candidate includes ZYNLONTA, camidanlumab tesirine, ADCT-602,... ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's product candidate includes ZYNLONTA, camidanlumab tesirine, ADCT-602, ADCT-601, ADCT-901, ADCT-701 and ADCT-212. Show more

Sector

Drugs And Proprietary-whsl

Industry

Drugs And Proprietary-whsl

Website

www.adctherapeutics.com

Headquarters

Lausanne, Che

Founded

ADC Therapeutics SA is listed in the Drugs And Proprietary-whsl sector of the New York Stock Exchange with ticker ADCT. The last closing price for ADC Therapeutics was $3.21. Over the last year, ADC Therapeutics shares have traded in a share price range of $ 0.9818 to $ 6.04.

ADC Therapeutics currently has 96,689,617 shares outstanding. The market capitalization of ADC Therapeutics is $310.37 million. ADC Therapeutics has a price to earnings ratio (PE ratio) of -1.32.

Form 4 - Statement of changes in beneficial ownership of securities

ADC Therapeutics Announces The Lancet Haematology Publication of Data from Investigator-Initiated Trial Evaluating ZYNLONTA® in Combination with Rituximab to Treat Relapsed/Refractory Follicular Lymphoma

ADC Therapeutics Announces The Lancet Haematology Publication of Data from Investigator-Initiated Trial Evaluating ZYNLONTA® in Combination with Rituximab to Treat Relapsed/Refractory Follicular...

ADC Therapeutics Announces Investigator-Initiated Study Abstracts Accepted for Presentation at the 66th ASH Annual Meeting

ADC Therapeutics Announces Investigator-Initiated Study Abstracts Accepted for Presentation at the 66th ASH Annual Meeting PR Newswire LAUSANNE, Switzerland, Nov. 5, 2024 Oral presentation of...

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	0.87	38.3259911894	2.27	3.39	1.8	2746334	3.01213363	CS
4	0.19	6.4406779661	2.95	3.39	1.8	1075201	2.78570501	CS
12	0	0	3.14	3.45	1.8	594708	2.91070794	CS
26	-0.25	-7.37463126844	3.39	4.13	1.8	537283	3.03067916	CS
52	2.09	199.047619048	1.05	6.04	0.9818	656474	3.26113969	CS
156	-17.36	-84.6829268293	20.5	22.52	0.359908	490993	3.89831239	CS
260	-26.86	-89.5333333333	30	56.5899	0.359908	407621	9.40286583	CS

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
BCHBanco de Chile	$ 26.45 (13.08%)	1
BPTBP Prudhoe Bay Royalty Trust	$ 0.835 (11.33%)	254
AIC3 AI Inc	$ 45.79 (9.86%)	385.29k
NRDYNerdy Inc	$ 1.80 (9.76%)	310
BBAIBigBear ai Holdings Inc	$ 3.94 (7.65%)	369.95k
YEXTYext Inc	$ 7.53 (-11.62%)	520
WKWorkiva Inc	$ 92.01 (-10.08%)	5
VHIValhi Inc	$ 22.30 (-9.72%)	172
SPRUSpruce Power Holding Corporation	$ 2.50 (-8.42%)	17
ORCLOracle Corp	$ 174.60 (-8.32%)	255.89k
NIONIO Inc	$ 4.94 (-4.63%)	1.39M
QBTSD Wave Quantum Inc	$ 4.81 (3.44%)	741.13k
IONQIonQ Inc	$ 34.065 (-0.51%)	486.66k
AIC3 AI Inc	$ 45.79 (9.86%)	385.39k
BBAIBigBear ai Holdings Inc	$ 3.93 (7.38%)	370.41k